Table IV.
Association of CTAG2 expression with the clinicopathological features of hepatocellular carcinoma patients from The Cancer Genome Atlas database.
| CTAG2 expression, n (%) | |||||
|---|---|---|---|---|---|
| Characteristic | Categories | n | Low | High | P-value |
| Sex | Female | 121 | 56 (46.3) | 65 (53.7) | 0.598 |
| Male | 250 | 123 (49.2) | 127 (50.8) | ||
| Age, years | <60 | 169 | 96 (56.8) | 73 (43.2) | 0.003 |
| ≥60 | 201 | 83 (41.3) | 118 (58.7) | ||
| T stage | 1 | 181 | 96 (53.0) | 85 (47.0) | 0.028 |
| 2 | 94 | 39 (41.5) | 55 (58.5) | ||
| 3 | 80 | 40 (50) | 40 (50) | ||
| 4 | 13 | 2 (15.4) | 11 (84.6) | ||
| TNM stage | 1 | 171 | 93 (54.4) | 78 (45.6) | 0.028 |
| 2–4 | 176 | 75 (42.6) | 101 (57.4) | ||
| AFP level | Low (<upper limit) | 120 | 67 (55.8) | 53 (44.2) | 0.045 |
| High (≥upper limit) | 158 | 69 (43.7) | 89 (56.3) | ||
P-value was obtained from Pearson's χ2 test or fisher's exact test. CTAG2, cancer/testis antigen 2; AFP, α-fetoprotein.